Overview

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

Status:
Completed
Trial end date:
2016-06-30
Target enrollment:
Participant gender:
Summary
To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
Phase:
Phase 3
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Treatments:
Trifluridine